Lescol Depot (Fluvastatin Sodium)

Lescol Depot (fluvastatin sodium) is used to manage disorders of lipid metabolism and to reduce cardiovascular risk.

• Hypercholesterolemia: lowers LDL‑cholesterol and total cholesterol levels, helping to achieve target lipid goals.
• Primary hyperlipidemia: improves overall lipid profile, reducing LDL‑cholesterol and modestly decreasing triglyceride concentrations.
• Secondary prevention of cardiovascular disease: decreases incidence of myocardial infarction, stroke, and other atherosclerotic events in patients with elevated cholesterol.
• Familial hypercholesterolemia: provides significant cholesterol reduction in genetically high‑cholesterol patients when combined with diet and lifestyle measures.
• Mixed dyslipidemia: helps normalize both LDL‑cholesterol and triglyceride levels, contributing to a more balanced lipid spectrum.

• Fluvastatin sodium competitively inhibits HMG‑CoA reductase, the key enzyme that catalyzes the conversion of HMG‑CoA to mevalonate in the hepatic cholesterol biosynthetic pathway. By blocking this rate‑limiting step, hepatic cholesterol synthesis declines, leading to up‑regulation of LDL receptors on hepatocyte surfaces and increased clearance of circulating LDL particles, thereby reducing plasma LDL‑cholesterol and total cholesterol concentrations.

Fluvastatin sodium may be associated with a range of adverse reactions, which are generally categorized by frequency and severity, and most are reversible upon discontinuation.

Common Side Effects

• Headache: mild to moderate headache that may occur intermittently, often responding to simple analgesics.
• Myalgia: muscle aches or stiffness without significant weakness, usually transient and dose‑related.
• Gastrointestinal discomfort: nausea, abdominal pain, dyspepsia or loss of appetite, which may improve with food.
• Elevated liver enzymes: transient mild increases in ALT or AST levels, typically monitored through routine labs.

Serious or Rare Side Effects

• Rhabdomyolysis: severe muscle breakdown leading to myoglobinuria, elevated CK levels, and potential renal failure, requiring immediate medical care.
• Hepatotoxicity: marked elevation of liver transaminases, hepatitis, or liver failure, necessitating cessation of therapy and monitoring.
• Allergic reactions: rash, pruritus, urticaria, or angioedema that may require antihistamines or emergency treatment.

When prescribing fluvastatin sodium, clinicians should consider several precautionary measures to ensure safe use.

• Liver function monitoring: assess baseline ALT/AST levels before initiation and repeat periodically during therapy.
• Drug interactions: review concomitant medications, especially CYP3A4 inhibitors, that may increase statin exposure.
• Renal impairment: use with caution in patients with severe renal dysfunction and adjust dosing as needed.
• Pregnancy and lactation: avoid use unless the potential benefits justify the possible risks to the fetus or infant.
• Muscle symptoms: discontinue therapy and evaluate for rhabdomyolysis if unexplained muscle pain, tenderness, or weakness develops.
• Store at ambient temperature: keep tablets in the original container, protect from moisture and light.

Fluvastatin sodium can interact with other medicines, influencing its plasma concentration and safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, HIV protease inhibitors): can cause a marked increase in fluvastatin plasma concentrations, raising the risk of myopathy or rhabdomyolysis.
• Gemfibrozil: concurrent use markedly raises statin exposure and significantly increases the risk of severe muscle toxicity.
• Cyclosporine: co‑administration enhances fluvastatin levels, leading to a higher incidence of muscle‑related adverse events.

Moderate Interactions (Monitor Closely)

• Anticoagulants such as warfarin: fluvastatin may potentiate anticoagulant effect, so INR should be monitored more frequently.
• Digoxin: statin therapy can increase digoxin concentrations; monitor serum digoxin levels for signs of toxicity.
• Antacids containing aluminum or magnesium hydroxide: may reduce fluvastatin absorption, potentially decreasing lipid‑lowering efficacy; consider timing separation.